Qualigen therapeutics secures option to negotiate license for g-quadruplex anti-cancer technology from ucl

Carlsbad, calif., march 01, 2021 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today it has entered into a material evaluation and option agreement with the university college london (ucl) to advance development of and potentially expand toward future commercial uses of qualigen's leading anticancer drug candidate as1411-gnp, also known as alan (aptamer-linked anti-nucleolin).
QLGN Ratings Summary
QLGN Quant Ranking